Abstract
Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Current Pharmaceutical Biotechnology
Title: Fibrinolytic Factors in Liver Fibrosis
Volume: 12 Issue: 9
Author(s): Liang-I Kang and Wendy M. Mars
Affiliation:
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Abstract: Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Export Options
About this article
Cite this article as:
Kang Liang-I and M. Mars Wendy, Fibrinolytic Factors in Liver Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281036
DOI https://dx.doi.org/10.2174/138920111798281036 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Pharmacotherapeutic Approach to Prevent or Treat Chronic Allograft Nephropathy
Current Drug Targets - Cardiovascular & Hematological Disorders Chronic Kidney Disease and the Risk of Cardiovascular Disease Events: A Community-Based Approach
Vascular Disease Prevention (Discontinued) Meet Our Editorial Board Member
Mini-Reviews in Organic Chemistry Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Physical Activity and Hypertension: Evidence of Cross-Sectional Studies,Cohort Studies and Meta-Analysis
Current Hypertension Reviews Nanoemulsion for Migraine Prophylaxis Nasal Drug Delivery: Preparation, Characterization and in vitro Evaluation
Pharmaceutical Nanotechnology Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine New Trends in Thromboxane and Prostacyclin Modulators
Current Medicinal Chemistry The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets